Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Unique Biotech Limited is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. PAGUIO FRISING, MICHELLE F is the busiest examiner for the company, with 1 pending action currently assigned. This distribution shows that each of the 2 pending office actions is being handled by a different examiner in a different art unit.
The involvement of 2 distinct art units suggests the filings cover diverse biological or pharmaceutical topics. With 2 pending office actions and 2 distinct examiners, the company's prosecution efforts are divided between two separate specialized groups. PAGUIO FRISING, MICHELLE F is responsible for 1 of the 2 pending actions, indicating an even split in the workload. This lack of concentration across the 2 distinct examiners requires the applicant to adapt to different examination styles. The focus on the Biotechnology & Pharmaceuticals area remains the common thread across both pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18609015 | Multi-strain probiotic formulation for ameliorating or preventing symptoms of treatment resistant depression | PAGUIO FRISING, MICHELLE F | 3d overdue |
| 18430704 | Probiotic composition comprising Bacillus clausii UBBC-07 for modifying Gut microbiome in IBD patients | DICKENS, AMELIA NICOLE | 63d |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18609015 | Multi-strain probiotic formulation for ameliorating or preventing symptoms of treatment resistant depression | PAGUIO FRISING, MICHELLE F | 1651 | §102§112DP | Final Rejection | 3d overdue | Pending | Mar 19, 2024 |
| 18430704 | Probiotic composition comprising Bacillus clausii UBBC-07 for modifying Gut microbiome in IBD patients | DICKENS, AMELIA NICOLE | 1645 | §103 | Final Rejection | 63d | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUnique Biotech Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Michelle F Paguio Frising has the most, with 1 of Unique Biotech Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
